X0202 4 2007-12-06 0 0001339455 Somaxon Pharmaceuticals, Inc. SOMX 0001024004 HALE DAVID F C/O SOMAXON PHARMACEUTICALS 3721 VALLEY CENTRE DRIVE, SUITE 500 SAN DIEGO CA 92130 1 1 0 0 Interim CEO & Executive Chmn Common Stock 20000 D Common Stock 2000 I By Family Trust Common Stock 228107 I By Hale Family Trust UTD 2/10/86 Stock option (right to buy) 5.90 2007-12-06 4 A 0 50000 A 2017-12-05 Common Stock 50000 50000 D Stock option (right to buy) 5.90 2007-12-06 4 A 0 40000 A 2007-12-06 2017-12-05 Common Stock 40000 40000 D 5,000 shares of this restricted stock award vest upon the acceptance of the New Drug Application ("NDA") with the Food and Drug Administration for the Company's lead product candidate, SILENOR and 15,000 shares vest upon the approval of the NDA for SILENOR. By brother of the reporting person, Michael T. Hale, as trustee, UDT December 26, 1996 for the benefit of the reporting person's son, David G. Hale. The reporting person disclaims beneficial ownership of these securities, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership for purposes of Section 16 or any other purpose. The option vests in 36 equal monthly installments of 1/36 of the number of shares subject to the option on the first day of each calendar month beginning January 2008. Not applicable to this transaction. /s/ Matthew Onaitis, Attorney-in-fact 2007-12-10